Portal vein complications in pediatric living donor liver transplantation using left-side grafts.
The aim of this report is to assess the rate of portal vein complications (PVCs), the success rate of treatment for PVCs and the prognosis of patients with PVCs for pediatric living donor liver transplantation (LDLT). Pre- and postoperative records of 521 pediatric LDLTs, using left-side grafts were retrospectively reviewed. The overall rate of PVC was 9%, with early PVC occurring in nine patients (1.7%) with a mortality rate of 67% and late PVC in 38 patients (7.3%). Fifteen of these patients with late PVC showed complete portal vein occlusion despite various treatments, and in six of them the graft was lost. Histological examination revealed fibrosis in portal areas in 13 patients, around the central veins associated with cholestasis in the parenchyma in 10, and hepatocyte ballooning in 12. Correction of portal vein flow or retransplantation is necessary for the rescue of patients with early PVCs. Graft loss in the long term may be high with the occurrence of liver failure or portal hypertension related causes, such as hepatopulmonary syndrome and gastrointestinal bleeding in patients with late PVCs. For the rescue of these patients, especially for patients with body weight < 6 kg, regular monitoring of portal vein flow is essential.
Ueda
M
M
Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. mikiko@kuhp.kyoto-u.ac.jp
Oike
F
F
Kasahara
M
M
Ogura
Y
Y
Ogawa
K
K
Haga
H
H
Takada
Y
Y
Egawa
H
H
Tanaka
K
K
Uemoto
S
S
D000293:Adolescent; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D005260:Female; D005355:Fibrosis / Q000209:etiology / Q000473:pathology; D006498:Hepatectomy / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008099:Liver / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods*; D019520:Living Donors; D008297:Male; D011169:Portal Vein / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome